Polpharma Biologics S.A. is required to prepare and publish information on the executed tax strategy in order to fulfill the obligation set forth in Article 27c paragraph 1 in connection with Article 27b paragraph 2 points 1 and 2 of the Corporate Income Tax Act of February 15, 1992. We invite you to read the document.
Information on the implemented tax strategy for 2023
- Published:
- written by: Polpharma Biologics
Related news
Other news related to this topic that may be of interest to you
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Rotkreuz – 31 July 2026 – Polpharma Biologics International AG today announces that the U.S. Food and...
Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus®...
Polpharma Biologics and PSI CRO Collaborate on Phase 1 Biosimilar Study in Multiple Sclerosis
June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...
Polpharma Biologics and Tuteur sign a licensing agreement for a biosimilar targeting autoimmune diseases
May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development...